Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
33 results
D1.149 - Murine IgG1 increased y subcutaneous immunotherapy suppressed development of allergic asthma
D1.150 - Study design for the saFety assessment of an Accelerated up-dosing scheme using one Strength of a native house dust mite allergen extract for subcutaneous immunoTherapy in children with allergic asthma in China (FAST II study)
D1.152 - Incidence of patients who needed to change their allergy immunotherapy product specific to mites or pollens in Spanish allergy unitsIncidence of switching specific allergic immunotherapy products in Spanish allergy units
D1.153 - Protocol for a randomized, 5-arm study to evaluate the combination of omalizumab and allergen immunotherapy in patients with asthma due to house dust mites
D1.154 - Safety of ultra-rush immunotherapy starting protocol with the molecular extract Diater Alt a 1 mol mix
D1.155 - Alterations in B cell memory induced by house dust mite allergen immunotherapy
D1.156 - Early Immunologic Parameters Predicting Response to Sublingual Immunotherapy in Allergic Rhinitis Patients
D1.157 - Type II Cytokine-Mediated Regulation of Alarmin Receptors in B Cells: Implications for Eosinophilic Esophagitis
D1.159 - The successful resolve of nasal polyps in patient with dupilumab treatment
D2.294 - Allergic contact dermatitis unit at Hospital Joan XXIII (Tarragona, Spain): descriptive analysis 2022 - 2023
D2.295 - Characterization of Treatment-Refractory Chronic Urticaria: A Large-Scale Retrospective Analysis of Clinical and Laboratory Parameters
D2.296 - Allergic contact dermatitis caused by a oxybutynin in a transdermal patch
D2.297 - SEP-631: A Novel Selective and Potent Oral MRGPRX2 Inhibitor for the Treatment of Chronic Spontaneous Urticaria
D2.299 - A novel synthetic molecule LN49 suppressed oxidative stress and inflammation in skin epithelial and fibroblast cells via activating Nrf-2 signaling pathway
D2.300 - Fixed Drug Eruption related to the use of NSAIDs
D2.302 - Non - immediate hypersensitivity to oxybutynin, first confirmed case with lymphocyte transformation test
D2.303 - Blistering Discovery: A Rare Case of Toxic Epidermal Necrolysis Triggered by Carboplatin and Radiotherapy
D2.304 - Transepidermal Water Loss in Atopic Diseases
D2.305 - Acute generalized exanthematous pustulosis due to iohexol with tolerance to iobitridol
D2.306 - Sodium dodecyl sulfate impairs the skin epithelial barrier by inducing oxidative stress in human skin
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download